From the Polynovo update:This pilot human trial is designed to...

From the Polynovo update:

This pilot human trial is designed to evaluate the feasibility of replacing the current non-degradable VAC device wound interface with a NovoSorb product. Key elements of the trial protocol to test the safety and suitability of the NovoSorbTM product will be as follows:
• 20 patients randomised with10 using NovoSorbTM and 10 using Granufoam® dressings;
• The current standard of care including 3 dressing changes per week will be adopted;
• Treatment duration of up to 8 weeks, less if the wound bed is suitable for definitive closure by skin graft;
• Disease indication - Sacral pressure sores; and
• Single study site (Royal Adelaide Hospital)

The open question is this: If dressings are to be changed three times a week, what therapeutic advantage is expected from using a biodegradable Novosorb dressing?